BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MaxCyte (MXCT)MaxCyteEarnings

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will

Open original release

Related news

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MXCTMaxCyte2026-02-23 21:05 EST

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

KRYSKrystal Biotech2026-04-21 12:00 EST

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

TSHATaysha Gene Therapies2026-04-29 12:00 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

KRYSKrystal Biotech2026-07-23 21:00 EST

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

SANASana Biotechnology2026-05-11 20:05 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-05-11 11:30 EST

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

TSHATaysha Gene Therapies2026-05-06 12:00 EST

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

MaxCyte

MaxCyte is a cell-engineering tools company that provides electroporation platforms used in cell therapy and gene therapy development. Its products support advanced-therapy manufacturing and research workflows.

Recent company news

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MXCTMaxCyte2026-04-29 20:05 EST

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MXCTMaxCyte2026-03-31 20:05 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-03-24 20:05 EST

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MXCTMaxCyte2026-03-23 12:05 EST

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Stock data

Close
1.02 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States